{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-237220","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2024-10-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.229865+00:00","generated_at":"2026-05-30T14:30:12.241865+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vanda rejects Cycle Group's $8.00/share acquisition proposal as undervaluing company","bullets":["Board unanimously determined second unsolicited proposal from Cycle Group not in best interests; terms identical to earlier May bid.","Proposal valued at $8.00/share in cash; Board says it substantially undervalues Vanda.","Board cited clinical pipeline, commercial presence, and cash balance as sources of greater value.","Second Cycle Group proposal received Sept 23, 2024; prior proposal May 24, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-237220","json":"https://secwatch.observer/filing/0001193125-24-237220.json","markdown":"https://secwatch.observer/filing/0001193125-24-237220.md","text":"https://secwatch.observer/filing/0001193125-24-237220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000119312524237220/0001193125-24-237220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000119312524237220/d840698d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T14:30:12.241865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}